Renalytix plc (LSE: RENX; OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, has announced it will present and exhibit at the Mello2026 investor event on Tuesday 17 November 2026 in London. Chief Executive James McCullough is scheduled to deliver two presentations during the day, covering company strategy and an overview of operations. The event provides Renalytix with a platform to reach retail and institutional investors at a prominent UK investor conference, as the company continues its commercialisation of the AI-enabled kidneyintelX.dkd diagnostic test.

Key Points

  • Renalytix plc (LSE: RENX; OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company focused on kidney disease management.
  • CEO James McCullough will present twice at Mello2026 on 17 November 2026 at The Clayton Hotel and Conference Centre, Chiswick High Road, London.
  • Presentation times are confirmed as 11:50am and 4:10pm; a PDF of the slides will be published on the company's investor website.
  • Investors may watch for updated commercial or strategic commentary from management following the presentations.

James McCullough Scheduled for Two Mello2026 Slots on 17 November

According to the announcement, Renalytix CEO James McCullough will take to the stage at 11:50am and again at 4:10pm on 17 November 2026 at The Clayton Hotel and Conference Centre on Chiswick High Road, London. Each session is described as providing an overview of the company and its strategy. A PDF copy of the presentation is expected to be made available on the company's investor relations website at investors.renalytix.com following the event, giving shareholders and prospective investors access to the material shared on the day.

kidneyintelX.dkd: FDA-Authorised AI Diagnostic Targeting Diabetic Kidney Disease

Renalytix's core commercial product is kidneyintelX.dkd, an AI-enabled in vitro diagnostic test designed to identify patients at risk of progressive decline in kidney function during the earliest stages of diabetic kidney disease. The company states that the test has received FDA authorisation and Medicare reimbursement, and is offered commercially throughout the United States. The technology is intended to help clinical teams prioritise resources and guideline-recommended treatments to improve renal and cardio-metabolic outcomes, addressing a condition the company describes as one of the largest cost and health burdens in both the US and UK healthcare systems.

Diabetic Kidney Disease Affects an Estimated 23 Million People Across the US and UK

The announcement highlights the scale of the market opportunity underpinning Renalytix's commercial strategy. The company states that unrecognised and uncontrolled diabetic kidney disease affects approximately 15 million people in the United States and 8 million people in the United Kingdom. The company operates across both markets, with its shares listed on the London Stock Exchange and trading on the OTCQB in the US, reflecting its dual-market focus. This patient population represents the addressable base for kidneyintelX.dkd as Renalytix pursues broader clinical adoption.